Oncotarget

Research Papers:

Downregulation of microRNA-31 inhibits proliferation and induces apoptosis by targeting HIF1AN in human keloid

Juan Zhang, Dan Xu, Na Li, Yan Li, Yongjing He, Xingbo Hu, Lechun Lyu _ and Li He

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:74623-74634. https://doi.org/10.18632/oncotarget.20284

Metrics: PDF 1668 views  |   HTML 2734 views  |   ?  


Abstract

Juan Zhang1,2,*, Dan Xu1,*, Na Li1,*, Yan Li1,*, Yongjing He3, Xingbo Hu4, Lechun Lyu1,2 and Li He1

1Department of Dermatology, the First Affiliated Hospital of Kunming Medical University, Kunming, China

2Department of Physiology, Kunming Medical University, Kunming, China

3Department of Plastic Surgery, Second Affiliated Hospital of Kunming Medical University, Kunming, China

4Department of Orthopedics, the First People’s Hospital of Kunming, Kunming, China

*Authors contributed equally to this work

Correspondence to:

Lechun Lyu, email: [email protected]

Li He, email: [email protected]

Keywords: keloid, microRNA-31, proliferation, apoptosis, cell cycle

Received: April 26, 2017    Accepted: July 12, 2017    Published: August 16, 2017

ABSTRACT

microRNAs (miRNAs) play a pivotal role in the regulation of cell proliferation and apoptosis in keloid scarring. Integrative analysis of the previous miRNA microarray revealed miRNA-31 was among the most frequently altered miRNAs in keloid and hypertrophic scar. Using qRT-PCR, we further validated miRNA-31 was increased in keloid tissues and keloid-derived fibroblasts. Moreover, downregulation of miRNA-31 inhibited the cell proliferation, induced the cell apoptosis and disturbed the cell cycle progression by targeting HIF1AN, a negative modulator of hypoxia inducible factor 1. Through the luciferase reporter assay, HIF1AN was confirmed to be a target of miRNA-31. Further studies demonstrated that miRNA-31 regulated proliferation, apoptosis and cell cycle of keloid-derived fibroblasts by mediating HIF1AN/VEGF signaling pathway. Overall, our findings shed new light on miRNA-31 as a promising therapeutic target in keloid scarring.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20284